

LEUKOMAX® Leukopaks

Single Donor, Billions of Cells

BioIVT offers LEUKOMAX® leukopak units from our more than 400 recallable human donors collected at all our FDA-/HTA-licensed donor centers under IRB-approved regimens using the Sepctra Optia® Apheresis System.



Available in Fresh and Cryopreserved Formats

Leukopak Size	Total Number of PBMCs*
Quarter	1-2 Billion
Half	3-4 Billion
Full	6-8 Billion

* Values estimated

Cell Type	Percentage per Leukopak*
T Cells	57% range 45-60%
Monocytes	20% range 10-30%
B Cells	10% range 5-15%
NK Cells	7.5% range 5-10%
Granulocytes	5.2% range 0.6%-10%
CD34+ Stem Cells	0.3% range 0.1-0.5%

With our global network of donor centers, your research doesn't have to wait!

- Same-day, fresh leukopak deliveries within 200 miles of our donor centers in:
 - Boston
 - Mid-Atlantic
 - San Francisco
 - London
- Customize your collection with peripheral blood mononuclear cell (PBMC) or immune cell subset isolations
- Donor demographic information available, including:
 - Age
 - Gender
 - HLA-type
 - Smoking status
 - Ethnicity
 - Medications & surgical history

With over 35 years as providers of high-quality biospecimens and related services, you can be sure that any of our LEUKOMAX® leukopak products are collected with support from dedicated personnel for ethical sourcing, quality control, auditing, and project management – all underpinned by our strong quality management system

Order Today at [BioIVT.com](https://www.bioivt.com)

For more information on BioIVT's donor screening, viral testing, and collection processes, visit our leukapheresis collections page



Maximize your cell count with mobilized leukopaks

Mobilized LEUKOMAX® leukopak units provide a rich source of CD34+ hematopoietic stem cells compared to traditional leukopaks. Donors are prepped with:


- Granulocyte-colony stimulating factor (G-CSF), or Neupogen® - FDA approved
- Plerixafor, or Mozobil®

Description	Average* WBC Yield	Average* CD34+ Yield	Days						
			1	2	3	4	5	6	
Mozobil X1 Collect Day 2	2.5 x 10 ¹⁰	1.2 - 2.5 x 10 ⁸	Mozobil	Collect					
Mozobil X2 Collect Days 2 & 3	5 x 10 ¹⁰	2.5 - 5 x 10 ⁸	Mozobil	Mozobil Collect	Collect				
Neupogen X5 Mozobil X2 Collect Days 5 & 6	9 x 10 ¹⁰	4.5 - 9 x 10 ⁸	Neupogen	Neupogen	Neupogen	Neupogen Mozobil	Neupogen Mozobil	Collect	
Neupogen X5 Mozobil X1 Collect Days 5 & 6	8 x 10 ¹⁰	4 - 8 x 10 ⁸	Neupogen	Neupogen	Neupogen	Neupogen Mozobil	Neupogen Collect	Collect	
Neupogen X5 Days 5 & 6	7 x 10 ¹⁰	3.5 - 7 x 10 ⁸	Neupogen	Neupogen	Neupogen	Neupogen	Neupogen Collect	Collect	

* Values estimated

Disease state leukopaks for your therapeutic indication

Want to get closer to real-world starting material? Disease progression, treatment history, and comorbidities may drastically affect donor immune cells in ways that normal donor immune cells just can't emulate. Whether it's drug discovery, cell or gene therapy development, or verification and validation – BioIVT has you covered. See graphic for the disease states covered.



North America & Asia Pacific
 T +1 516 483 1196 F +1 516 483 4683
 E customerservice@bioivt.com

Europe, Middle East & Africa
 T +44 1444 707333 F +44 (0) 1444 250066
 E cseurope@bioivt.com